Abstract The glucagon-like peptide-1 (GLP-1) receptor, known as GLP-1R, is a vital
component of the G protein-coupled receptor (GPCR) family and is found primarily on the …

Steatotic liver disease (SLD) displays a dynamic and complex disease phenotype.
Consequently, the metabolic dysfunction-associated steatotic liver disease …

Metabolic dysfunction-associated steatotic liver disease (MASLD), previously termed non-
alcoholic fatty liver disease (NAFLD), is defined as steatotic liver disease (SLD) in the …

The history of anti-obesity pharmacotherapies is marked by disappointments, often
entangled with societal pressure promoting weight loss and the prevailing conviction that …

Background Fibroblast growth factor 21 (FGF21) regulates metabolism and protects cells
against stress. Efruxifermin is a bivalent Fc–FGF21 analogue that replicates FGF21 agonism …

Obesity is a chronic disease associated with increased risk of obesity-related complications
and mortality. Our better understanding of the weight regulation mechanisms and the role of …

Background & Aims This was a randomized, double-blind, placebo-controlled study to
assess the effects of pemvidutide, a glucagon-like peptide-1 (GLP-1)/glucagon dual receptor …

Aim This systematic review and meta-analysis was conducted to evaluate the efficacy and
safety of 24 weeks of semaglutide treatment in patients with non-alcoholic fatty liver disease …

Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) pose a
significant threat to human health and cause a tremendous socioeconomic burden …

The prevalence and severity of metabolic dysfunction associated steatotic liver disease
(MASLD) are increasing. Physicians who treat patients with MASLD may acknowledge the …